Abacavir should be avoided by people who are in the high cardiovascular risk group.
Abacavir
Abacavir and heart attacks
From the March 2008 issue of Positive Living
Latest results presented by investigators at the CROI meeting in February in Boston suggested that treatment with abacavir (also found in the combination pills Kivexa and Trizivir) and ddI (didanosine, Videx) may significantly increase the risk of myocardial infarction, or heart attack.
IAS 2007: Promising signs
From the October 2007 issue of Positive Living
A major HIV/AIDS medical conference in Sydney has generated lots of news on the treatments front, reports Paul Kidd.
Getting spine: the nucleoside backbone
From the December 2005 issue of Positive Living
Nucleoside analogues are the backbone of successful anti-HIV treatments. This article examines some of the issues involved in selecting the best nucleoside backbone.
Kivexa available on PBS
From the October 2005 issue of Positive Living
Kivexa, a new single-pill combination of the antiviral drugs abacavir (Ziagen) and lamivudine (3TC) became available for S100 prescription from 1 December.
News and treatments briefs
From the February 2004 issue of Positive Living
HIV-related news in brief from the Feb-Mar 2004 edition of Positive Living.